Paratek Pharmaceuticals (PRTK) Lowered to Strong Sell at ValuEngine

ValuEngine downgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a research note published on Friday.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird reaffirmed a buy rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. Guggenheim initiated coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a buy rating and a $44.00 price objective on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, November 1st. Finally, BidaskClub cut shares of Paratek Pharmaceuticals from a sell rating to a strong sell rating in a research report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals has a consensus rating of Buy and an average target price of $40.00.

Get Paratek Pharmaceuticals alerts:

Paratek Pharmaceuticals (PRTK) traded down $0.25 on Friday, reaching $17.90. 253,304 shares of the company traded hands, compared to its average volume of 368,769. The company has a market cap of $507.13, a PE ratio of -4.80 and a beta of 0.70. Paratek Pharmaceuticals has a 1-year low of $13.95 and a 1-year high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

A number of large investors have recently modified their holdings of PRTK. Alyeska Investment Group L.P. lifted its position in Paratek Pharmaceuticals by 473.4% during the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock worth $23,000,000 after buying an additional 756,535 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Paratek Pharmaceuticals during the 3rd quarter worth about $8,598,000. State Street Corp lifted its position in Paratek Pharmaceuticals by 112.3% during the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock worth $14,850,000 after buying an additional 325,856 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in Paratek Pharmaceuticals by 90.8% during the 3rd quarter. Pictet Asset Management Ltd. now owns 661,995 shares of the specialty pharmaceutical company’s stock worth $16,616,000 after buying an additional 315,010 shares in the last quarter. Finally, Davidson Kempner Capital Management LP bought a new stake in Paratek Pharmaceuticals during the 3rd quarter worth about $6,727,000. 84.30% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Paratek Pharmaceuticals (PRTK) Lowered to Strong Sell at ValuEngine” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://theolympiareport.com/2017/12/30/paratek-pharmaceuticals-prtk-lowered-to-strong-sell-at-valuengine.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.